BioInvent seeks shareholder approval for SEK 430 million rights issue
Bitget2026/10/28 17:21- BioInvent seeks shareholder approval for an approximately SEK 430 million rights issue at an extraordinary general meeting scheduled for December 1, 2026.
- Proceeds will fund priority clinical programs, principally solid tumor treatments BI-1808 and BI-1206.
- Subscription commitments and guarantee undertakings cover approximately SEK 350 million, or 81%, of the rights issue.
- Van Herk Investments proposes electing Dharminder Chahal to the board at the meeting.
- Major shareholders and shareholding directors and management have committed or indicated their intention to vote for the rights issue and necessary resolutions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
